Berlin, 22 August 2006 -- Revotar Biopharmaceuticals AG, a portfolio-company of bmp AG (WKN 330420), has concluded a strategically significant agreement with a US pharmaceuticals manufacturer for the successful development and marketing of the compound Bimosiamose in the field of dermatology. In the course of the agreement, the US pharmaceuticals manufacturer - whose name it has been agreed, is to be kept confidential - will make a one-off payment to Revotar. In addition, an option for a development and licensing agreement has been granted. Milestones (payments as well as licence fees in the upper two figure million figure echelons) have already been stipulated. In 2000, bmp invested in the Berlin-based Revotar and currently maintains a 49.99 % holding in the company. Bimosiamose is a new selectin antagonist developed by Revotar for the treatment of inflammatory diseases. In the treatment of asthma and psoriasis, the agent is in the clinical phase II.
Oliver Bormann, CEO of bmp said, “With the conclusion of the agreement, the development of Revotar has taken a significant forward step.” Stephan Tarlach, CEO of Revotar added, “We are very pleased that we have found a partner who is just as convinced as we of the potential of our leading product Bimosiamose.”
About Bimosiamose: Within Revotar AG’s research and development programme, Bimosiamose is the most-developed synthetic pan-selectin antagonist. Bimosiamose has proven itself to be effective in countless animal models. In the early phase of the clinical development programme, good levels of tolerance, and a safe application were displayed in various pharmaceutical forms, including intravenous, hypodermic, topical and inhalational forms. In phase IIa “proof of concept” studies, Bimosiamose displayed effectiveness in the indicators asthma (inhalational application) and psoriasis (topical and hypodermic forms of application).
About Revotar Biopharmaceuticals AG: Revotar is a German biotechnology company, held by venture capital companies and private investors. The Brandenburg ministry of economics also provides financial support for the company. Revotar’s HQ is located in Henningsdorf in Berlin. Revotar researches and develops base molecular agents for the treatment of inflammation. The furthest-development product, Bimosiamose, a base molecular Pam selectin antagonist is already in an advanced stage of development. Thus data has already been obtained for the treatment of psoriasis and asthma in the clinical phase II. Further areas of application for selectin antagonists could be COPD (chronic obstructive pulmonary disease), acute lung failure or organ transplantation.
Further information about Revotar Biopharmaceuticals is to be found at www.revotar-ag.de
About bmp AG: As an internationally active company in the Private Equity Industry, bmp invests its own funds directly into equity investment while at the same time acting as a Funds Manager for others. bmp provides its trade investments not only with capital but also with the advantages of ten years of comprehensive business development know-how. With the experience it has gained from more than 80 trade investments of its own, 12 Initial Public Offerings and more than 20 trade sales from its portfolio, bmp is numbered among the most competent venture capital companies in Germany and Poland.
For further information:
bmp AG Corinna Riewe Investor Relations
Schlüterstraße 38 10629 Berlin Tel: 030-20 30 5-567 Fax: 030-20 30 55 32 E-mail: criewe@bmp.com Internet: www.bmp.com
